MDWD
MediWound·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Consensus Rating "Strong Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDWD
Mediwound Ltd.
A fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration
42 Hayarkon Street, Yavne , 8122745 Israel
--
MediWound Ltd., was legally incorporated in Israel on January 27, 2000. It is a fully vertically integrated biopharmaceutical company focused on developing, producing and commercializing new products to meet the therapeutic needs in the areas of severe burns, chronic and other difficult-to-heal wounds and connective tissue diseases. Its innovative biomedical product NexoBrid was approved for marketing by the European Medicines Agency (EMA) in December 2012 to remove dead or damaged tissue (i.e. eschar) and treat local and systemic thermal burns (i.e. severe burns). NexoBrid, based on its patented proteolytic enzyme technology, represents a new model in burn care, and the company's clinical trials have shown statistically significant that patients can achieve rapid early eschar removal without hospitalization, non-surgical, and no additional tissue damage. Through its wholly-owned subsidiary in Germany, the company launched NexoBrid in the EU in December 2013, targeting burn patients in burn centers and hospital burn units. The company also plans to initiate a Phase 3 pivotal study in the United States in the first half of 2014 to file a biological product license application (or BLA) with the U.S. Food and Drug Administration (FDA). The company's headquarters in Yavne, Israel has a state-of-the-art, EMA-certified, CGMP-compliant, sterile pharmaceutical manufacturer. And NexoBrid is produced here.
Earnings Call
Q1/2025
Estimate EPS-0.66
Actual EPS-0.07
Estimate Revenue5.20M
Actual Revenue3.96M
MediWound's Q1 2025 Earnings Call: Unraveling Contradictions in Facility Readiness and Regulatory Timelines
May 21,2025 12:54
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.57
Actual EPS-1.23
Estimate Revenue5.68M
Actual Revenue5.71M
MediWound's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Capacity, Stockpiling, and Regulatory Approvals
Aug 14,2025 01:39
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MDWD has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected -0.83, beating expectations. The chart below visualizes how MDWD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MDWD has released its 2025 Q3 earnings report, with revenue of 5.43M, reflecting a YoY change of 24.66%, and net profit of -2.65M, showing a YoY change of 74.21%. The Sankey diagram below clearly presents MDWD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
